

(ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than September 24, 2012.

Dated: July 17, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-18203 Filed 7-25-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 4, 2012, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug   | Schedule |
|--|----------|
| Gamma Hydroxybutyric Acid (2010)                   | I        |
| Amphetamine (1100)                                 | II       |
| Lisdexamfetamine (1205)                            | II       |
| Methylphenidate (1724)                             | II       |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP)(8333)    | II       |
| Phenylacetone (8501)                               | II       |
| Cocaine (9041)                                     | II       |
| Codeine (9050)                                     | II       |
| Oxycodone (9143)                                   | II       |
| Hydromorphone (9150)                               | II       |
| Hydrocodone (9193)                                 | II       |
| Methadone (9250)                                   | II       |
| Dextropropoxyphene, bulk (non-dosage forms) (9273) | II       |
| Morphine (9300)                                    | II       |
| Oripavine (9330)                                   | II       |
| Thebaine (9333)                                    | II       |
| Opium, raw (9600)                                  | II       |
| Opium extracts (9610)                              | II       |
| Opium fluid extract (9620)                         | II       |
| Opium tincture (9630)                              | II       |
| Opium, powdered (9639)                             | II       |
| Opium, granulated (9640)                           | II       |
| Oxymorphone (9652)                                 | II       |
| Noroxymorphone (9668)                              | II       |
| Poppy Straw Concentrate (9670)                     | II       |
| Alfentanil (9737)                                  | II       |
| Remifentanil (9739)                                | II       |
| Sufentanil (9740)                                  | II       |
| Fentanyl (9801)                                    | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies.

Any other such applicant, and any person who is presently registered with

DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than September 24, 2012.

Dated: July 17, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-18212 Filed 7-25-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application; Boehringer Ingelheim Chemicals Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 8, 2012, Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805-9372, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                          | Schedule |
|-------------------------------|----------|
| Amphetamine (1100)            | II       |
| Lisdexamfetamine (1205)       | II       |
| Methylphenidate (1724)        | II       |
| Methadone (9250)              | II       |
| Methadone Intermediate (9254) | II       |
| Tapentadol (9780)             | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. In reference to Methadone Intermediate (9254) the company plans to produce Methadone HCL active pharmaceutical ingredients (APIs) for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive,

Springfield, Virginia 22152; and must be filed no later than September 24, 2012.

Dated: July 17, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration

[FR Doc. 2012-18202 Filed 7-25-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration, Cambrex Charles City, Inc.**

By Notice dated April 17, 2012 and published in the **Federal Register** on April 26, 2012, 77 FR 24986, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug               | Schedule |
|--------------------|----------|
| Hydrocodone (9193) | II       |
| Methadone (9250)   | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cambrex Charles City, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: July 17, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-18209 Filed 7-25-12; 8:45 am]

**BILLING CODE 4410-09-P**